Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Medipharm Labs Corp (OP: MEDIF )

0.0520 +0.0005 (+0.97%)
Streaming Delayed Price Updated: 1:26 PM EDT, Jul 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,025
Open 0.0523
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0515
Today's Range 0.0520 - 0.0523
52wk Range 0.0404 - 0.0769
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Executive Changes In Cannabis Industry You Should Know About, New Appointments & More
Shareholders of four cannabis companies held their respective annual meetings, electing nominees as board directors.Sandy Li, who has been serving at cannabis edibles producer Wana Brands since 2022 as... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabinoids-Focused MediPharm Boasts This Advanced Medical Cannabis Delivery Method
Cannabinoids-based pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Thursday that it has entered into a licensing agreement with Remidose Aerosols Inc. to... 
Via Benzinga
Topics Cannabis
Exposures Cannabis

Performance

YTD
+5.48%
+5.48%
1 Month
-6.81%
-6.81%
3 Month
-13.62%
-13.62%
6 Month
+7.44%
+7.44%
1 Year
+18.18%
+18.18%

More News

Read More
MEDIF Stock Earnings: MediPharm Labs Reported Results for Q1 2024
Via InvestorPlace
Cannabinoids-Focused Pharma Company, MediPharm, Sees Higher Q1 Revenue, CFO Touts 'Strong Financial Position'
Via Benzinga
MEDIF Stock Earnings: MediPharm Labs Reported Results for Q4 2023
Via InvestorPlace
The Canadian Cannabis Report - Monday, April 22
Via Talk Markets
Topics Cannabis
Exposures Cannabis
This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses
Via Benzinga
The Canadian Cannabis Report - Monday, March 25
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Canadian CBD-Focused Pharma Co. Gets Green Light To Produce Medical Marijuana In Brazil
Via Benzinga
Topics Cannabis
Exposures Cannabis Product Safety
Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024
Via Benzinga
Topics Cannabis
Exposures Cannabis
MediPharm Labs Still Hits C$8.5M Despite Sequential Drop, More On That In Q3 2023 Financial Report
Via Benzinga
New Cannabis Products Energize Global Health & Wellness Market, Including Australia
Via Benzinga
Topics Cannabis
Exposures Cannabis
MediPharm Settles Commercial Agreement Dispute With Tilray's Hexo For $9M
Via Benzinga
New CBD & THC Cannabis Oils Now Shipping To Australia From Canada
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Canadian Cannabis Report - Monday, Sept. 25
Via Talk Markets
Topics Cannabis
Exposures Cannabis
MediPharm Labs Breaks Free From Royalty Agreement, What It Means & What's Next
Via Benzinga
Could Medical Cannabis Be The Answer For Fibromyalgia? Here's What New Study Found
Via Benzinga
Topics Cannabis
Exposures Cannabis
Marijuana Stock Movers For August 23, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Gainers And Losers From August 24, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabinoid-Focused Pharma Stock Slides On Q2 Earnings Report, Here Are The Details
Via Benzinga
Cannabis Stock Gainers And Losers From August 16, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Marijuana Stock Movers For August 15, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Gainers And Losers From August 14, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Gainers And Losers From August 11, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Movers For August 10, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.